{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-070385","form_type":"8-K","ticker":"IRIX","cik":"0001006045","company_name":"IRIDEX CORP","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.137007+00:00","generated_at":"2026-05-21T12:18:17.964895+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iridex Q1 revenue $11.9M, positive adj EBITDA $0.4M after $10M strategic investment","bullets":["Total revenue $11.9M (flat YoY); Cyclo G6 glaucoma revenue up 8% to $3.2M; Retina revenue down 3% to $6.6M.","Adjusted EBITDA improved to $0.4M from ($2.5M) YoY; net loss narrowed to $1.7M ($0.10/share) from $3.5M ($0.21).","Operating expenses cut 32% to $5.3M; gross margin expanded to 42.5% from 37.9% on favorable product mix.","Received $10M strategic investment from Novel Inspiration; Lind note payable settled, reducing debt.","2025 outlook: cash flow breakeven and positive adjusted EBITDA on 2024-level revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-070385","json":"https://secwatch.observer/filing/0000950170-25-070385.json","markdown":"https://secwatch.observer/filing/0000950170-25-070385.md","text":"https://secwatch.observer/filing/0000950170-25-070385.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006045/000095017025070385/0000950170-25-070385-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006045/000095017025070385/irix-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T12:18:17.964895+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}